Study: Most head lice resistant to OTC allopathic remedies
NORWALK, Conn. — According to a report published Friday in HealthDay News, most head lice now carry a gene mutation that makes them resistant to standard over-the-counter treatments, citing a study in the March issue of the Journal of Medical Entomology.
As many as 88% of lice may carry the gene mutation.
"This gives most of today’s head lice an ability to withstand exposure to the main — and previously effective — ingredients found in most nonprescription head lice drugs: ‘pyrethroid’ compounds, such as permethrin," the report stated.
American Pharmacists Association’s Academy of Student Pharmacists names top school dean
STOCKTON, Calif. — The American Pharmacists Association’s Academy of Student Pharmacists has named Phillip R. Oppenheimer, who has led University of the Pacific’s Thomas J. Long School of Pharmacy and Health Sciences for almost two decades, as the 2014 Outstanding Dean.
The award recognizes Oppenheimer for promoting the education of student pharmacists through community service, leadership and professional activities.
Oppenheimer will receive the award during the American Pharmacists Association annual meeting in Orlando on March 28.
“Dean Oppenheimer is widely respected for his vision and innovation in pharmacy education, and for preparing pharmacists who will give back to their communities,” stated University of the Pacific president Pamela A. Eibeck. “He richly deserves this national honor.”
Under Oppenheimer’s leadership, the school has become a leading provider of care for underserved communities. Pharmacy students, working with faculty and preceptors, last year provided more than 100 free healthcare programs and served thousands of patients throughout Northern California, offering health screenings, immunizations and Medicare Part D clinics to help the elderly lower their annual prescription drug costs.
One-out-of-three pharmacists practicing in California has a degree from Pacific’s school of pharmacy. Graduates of the school, established in 1955, have included the CEO of the American Pharmacists Association and the presidents of the American Society of Consultant Pharmacists, Academy of Managed Care Pharmacy and American Society of Health System Pharmacists. Graduates attain among the nation’s highest passage rates on the Pharmacy Licensure examination.
Pharmacist Michael Patrick, past president of the California Pharmacists Association, noted Oppenheimer’s leadership in pharmacy education. He cited such curricular innovations as Pacific’s combined Pharm.D./Ph.D. and Pharm.D./MBA degree programs; its AmerisourceBergen Good Neighbor Pharmacy Entrepreneurial Pharmacy Practice Program, the first of its kind in pharmacy education; and its incorporation of traditional basic sciences coursework into an integrated approach to pharmaceutical care and disease state management.
Oppenheimer also established opportunities for students to gain early clinical practice in community and long-term care practice settings, well before such experiences became a requirement of the Accreditation Council for Pharmacy Education.
The son of a community pharmacist, Oppenheimer received his doctor of pharmacy degree from UCSF in 1972 and completed a clinical pharmacy residency, also at UCSF, in 1973. He joined Pacific as dean of the pharmacy school in 1997, following a 24-year career as a faculty member and administrator at the University of Southern California.
University of the Pacific’s Thomas J. Long School of Pharmacy and Health Sciences also encompasses speech-language pathology and physical therapy degree programs, and operates an audiology patient clinic. The school will open an additional audiology clinic at Pacific’s new San Francisco campus this summer, and next fall will introduce Northern California’s first doctor of audiology degree program.
Mallinckrodt receives FDA approval for Xartemis XR
DUBLIN — Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.
The drug also is indicated for patients for whom alternative treatments have shown to be ineffective. Xartemis XR, previously known as MNK-795, is the first and only extended-release oral combination of two clinically proven pain medications — oxycodone and acetaminophen.
Pain that is left uncontrolled or unmanaged results in significant costs to U.S. business in terms of lost productivity, according to the company. Data from the Institute of Medicine showed that in 2011, 80% of patients undergoing surgery experienced postoperative pain. Eighty-eight percent reported the pain to be moderate, severe or extreme.
“Acute pain doesn’t last for only four to six hours, and neither should its treatment. With the extended-release profile of XARTEMIS XR, patients may not need to wake in the night to take a dose,” said Nathaniel Katz, MD, MS, adjunct assistant professor of anesthesia at Tufts University School of Medicine. “A long-acting combination analgesic that can effectively deliver oxycodone and acetaminophen for acute pain patients experiencing pain throughout the day and night is a welcome addition to the treatment landscape.”